Natco Pharma — 360° view

Natco Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹967 crore and net profit of ₹203 crore for the September 2026 quarter.

Natco Pharma (NSE: NATCOPHARM) closed at ₹814.30 on 20 Nov 2026, down 6.3% over the past year. Its market capitalisation is ₹15,974 crore and it trades at 19.3 times earnings.

Share price
₹814.30 (20 Nov 2026)
Market cap
₹15,974 Cr (20 Nov 2026)
P/E
19.28 (20 Nov 2026)
Revenue
₹967 Cr (September 2026 quarter)
Net profit
₹203 Cr (September 2026 quarter)
ROCE
17.4% (FY26)
ROE
17.1% (FY26)
Book value
₹541 (FY26)
Dividend yield
0.52% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,226.80 / ₹773.60 (20 Nov 2026)
1-year return
-6.3% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: NATCOPHARM

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.